

Medical Coverage Policy | Prostatic Urethral Lifts



EFFECTIVE DATE: 12|01|2018

POLICY LAST UPDATED: 10|03|2017

OVERVIEW

Benign prostatic hyperplasia is a common condition in older men that can lead to increased urinary frequency, urgency, nocturia, hesitancy, and weak urinary stream. The prostatic urethral lift (PUL) procedure involves the insertion of 1 or more permanent implants into the prostate, which retract prostatic tissue and maintain an expanded urethral lumen.

MEDICAL CRITERIA

Blue CHiP for Medicare and Commercial Products

The prostatic urethral lift procedure is considered medically necessary when the ALL of the following criteria are met:

- The UroLift device is used for the treatment of symptomatic BPH when there is well documented voiding symptoms consistent with prostatic hypertrophy; and
- AUA symptom index (AUASI) score greater than or equal to 13; and
- Peak urine flow rate (Qmax) less than or equal to 12 cc/sec on a voided volume that is greater than 125 cc; and
- There has had an adequate trial of, but is refractory to or intolerant of, usual BPH medication; and
- The prostate volume is less than or equal to 80 cc without an obstructive median lobe; and
- There are no signs, symptoms, or diagnostic evidence of an active urinary infection and no history of bacterial prostatitis in the past three (3) months; and
- The beneficiary is a poor candidate for other surgical interventions for BPH due to underlying disease (e.g. cardiac disease, pulmonary disease, etc.) and/or at high risk of bleeding and/or the beneficiary has opted for PUL based on likelihood of preserving sexual function and/or there is another documented reason for opting for PUL.

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial Products.

POLICY STATEMENT

Blue CHiP for Medicare and Commercial Products

The prostatic urethral lift procedure is considered medically necessary when all of the criteria are met.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND

Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can lead to increased urinary frequency, an urgency to urinate, a hesitancy to urinate, nocturia, and a weak stream when urinating. The prostatic urethral lift (PUL) procedure involves the insertion of one or more permanent implants into the prostate, which retracts prostatic tissue and maintains an expanded urethral lumen.

Management

Evaluation and management of BPH include assessment for other causes of lower urinary tract dysfunction (eg, prostate cancer); symptom severity and the degree that symptoms are bothersome determine the therapeutic approach.

Medical Therapy

A discussion about medical therapy is generally indicated for patients with moderate-to-severe symptoms (eg, an AUASI score of ≥ 8), bothersome symptoms, or both. Available medical therapies for BPH-related lower urinary tract dysfunction include α -adrenergic blockers (eg, alfuzosin, doxazosin, tamsulosin, terazosin, silodosin), 5 α -reductase inhibitors (eg, finasteride, dutasteride), combination α -adrenergic blockers and 5 α -reductase inhibitors, anti-muscarinic agents (eg, darifenacin, solifenacin, oxybutynin), and phosphodiesterase-5 inhibitors (eg, tadalafil).¹ A 1999 meta-analysis of both indirect comparisons from placebo-controlled studies (including 6333 patients) and direct comparative studies (including 507 patients) found that the IPSS improved by 30% to 40% and the Qmax score (mean peak urinary flow rate) improved by 16% to 25% in individuals assigned to α -adrenergic blockers.⁴ Combination therapy using an α -adrenergic blocker and 5 α -reductase inhibitor has been shown to be more effective for improving IPSS than either treatment alone, with median scores improving by more than 40% over 1 year and by more than 45% over 4 years.⁵

Surgical and Ablative Therapies

Patients who do not have sufficient response to medical therapy, or who are experiencing significant side effects with medical therapy, may be referred for surgical or ablative therapies. Various surgical or ablative procedures are used to treat BPH. Transurethral resection of the prostate is generally considered the reference standard for comparisons of BPH procedures.⁶ In the perioperative period, transurethral resection of the prostate is associated with risks of any operative procedure (eg, anesthesia risks, blood loss). Although short-term mortality risks are generally low, 1 large prospective study with 10,654 patients reported the following short-term complications: “failure to void (5.8%), surgical revision (5.6%), significant urinary tract infection (3.6%), bleeding requiring transfusions (2.9%), and transurethral resection syndrome (1.4%).”⁷ Incidental carcinoma of the prostate was diagnosed by histologic examination in 9.8% of patients. In the longer term, transurethral resection of the prostate is associated with increased risk of sexual dysfunction and incontinence.

Several minimally invasive prostate ablation procedures have also been developed, including transurethral microwave thermotherapy, transurethral needle ablation of the prostate, urethromicroablation phototherapy, and photoselective vaporization of the prostate. The minimally invasive procedures were individually compared with transurethral resection of the prostate at the time they were developed, which provided a general benchmark for evaluating those procedures.

Prostatic Urethral Lift

The prostatic urethral lift procedure involves placement of one or more implants in the lateral lobes of the prostate using a transurethral delivery device. The implant device is designed to retract the prostate to allow expansion of the prostatic urethra. The implants are retained in the prostate to maintain an expanded urethral lumen.

One device, the NeoTract UroLift System, has been cleared for marketing by the U.S. Food and Drug Administration (FDA; see Regulatory Status section). The device has 2 main components: the delivery device and the implant. Each delivery device comes preloaded with a UroLift implant.

For individuals who have lower urinary tract obstruction symptoms (due to BPH) and receive a PUL, the evidence includes systematic reviews, randomized controlled trials, and noncomparative studies.

Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. One randomized controlled trial, the BPH6 study, compared the PUL procedure with transurethral resection of the prostate and reported that the PUL procedure was noninferior for the study’s composite end point, which required concurrent fulfillment of 6 independently validated measures of symptoms, safety, and sexual health. While transurethral resection of the prostate was superior to PUL in managing lower urinary tract symptoms, PUL did provide significant symptom improvement over 2 years. PUL was further superior to transurethral resection of the prostate in

preserving sexual function. These findings were corroborated by another randomized controlled trial, entitled the LIFT study, which compared PUL with sham control. Patients underwent washout of BPH medications before enrollment. LIFT reported that patients with the PUL procedure, compared with patients who had sham surgery and no BPH medication, had greater improvements in lower urinary tract symptoms without worsened sexual function at 3 months. After 3 months, patients were given the option to have PUL surgery; 80% of the patients with sham procedures chose that option. Publications from this trial reported that functional improvements were durable over 3-, 4-, and 5-year follow-ups in a subset of patients treated with PUL; there was a high number of exclusions and loss to follow-up in that group. The evidence is sufficient to determine the effects of the technology on health outcome

CODING

Blue CHiP for Medicare and Commercial Products

The following codes are medically necessary when the medical criteria is met:

52441 Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
52442 each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)

C9739 Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants (**For institutional providers use only**)

C9740 Cystourethroscopy, with insertion of transprostatic implant; 4 or more
Implants (**For institutional providers use only**)

RELATED POLICIES

None

PUBLISHED

Provider Update, November/December 2018

Provider Update, December 2017

Provider Update, January 2017

REFERENCES:

Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. *N Engl J Med.* Jul 19 2012;367(3):248-257. PMID 22808960

2. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association symptom index for benign

prostatic hyperplasia. The Measurement Committee of the American Urological Association. *J Urol.* Nov 1992;148(5):1549-1557; discussion 1564. PMID 1279218

3. O'Leary M P. Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic

hyperplasia. *Rev Urol.* Winter 2005;7(1):1-10. PMID 16985801

4. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in

patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. *Eur Urol.* Jun 1999;36(1):1-

13. PMID 10364649

5. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med.* Dec 18 2003;349(25):2387-2398. PMID 14681504

6. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of Benign

Prostatic Hyperplasia (BPH). 2010 (affirmed 2014); [http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-](http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-2010-reviewed-and-validity-confirmed-2014)

2010-reviewed-and-validity-confirmed-2014). Accessed November 7, 2017.

7. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol.* Jul 2008;180(1):246-249. PMID 18499179
8. Sundaram D, Sankaran PK, Raghunath G, et al. Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms. *J Clin Diagn Res.* May 2017;11(5):AC01-AC04. PMID 28658743
9. Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. *Urology.* May 2007;69(5):805-809. PMID 17482908
10. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *Int J Impot Res.* Jul-Aug 2005;17(4):307-319. PMID 15875061
11. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? *J Urol.* Nov 1995;154(5):1770-1774. PMID 7563343
12. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. *J Urol.* May 2012;187(5):1732-1738. PMID 22425127
13. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. *Med Care.* Apr 1995;33(4 Suppl):AS145-155. PMID 7536866
14. Perera M, Roberts MJ, Doi SA, et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol.* Apr 2015;67(4):704-713. PMID 25466940
15. Garrido Abad P, Coloma Del Peso A, Sinues Ojas B, et al. Urolift(R), a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results. *Arch Esp Urol.* Jul-Aug 2013;66(6):584-591. PMID 23985459
16. Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. *Cochrane Database Syst Rev.* Sep 12 2012;9(9):CD004135. PMID 22972068
17. Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can J Urol.* Feb 2014;21(1):7094-7101. PMID 24529008
18. McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *Eur Urol.* Aug 2013;64(2):292-299. PMID 23357348
19. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology.* Jan 2012;79(1):5-11. PMID 22202539
20. Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med.* Feb 2012;9(2):568-575. PMID 22172161
21. Woo HH, Chin PT, McNicholas TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *BJU Int.* Jul 2011;108(1):82-88. PMID 21554526

22. Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *BJU Int.* Apr 2014;113(4):615-622. PMID 24765680
23. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol.* Dec 2013;190(6):2161-2167. PMID 23764081
24. McVary KT, Gange SN, Shore ND, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med.* Jan 2014;11(1):279-287. PMID 24119101
25. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol.* Jun 2015;22(3):7772-7782. PMID 26068624
26. Shore N. A review of the prostatic urethral lift for lower urinary tract symptoms: symptom relief, flow improvement, and preservation of sexual function in men with benign prostatic hyperplasia. *Curr Bladder Dysfunct Rep.* Mar 27 2015;10(2):186-192. PMID 25984251
27. Jones P, Rajkumar GN, Rai BP, et al. Medium-term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. *Urology.* Nov 2016;97:20-24. PMID 27208817
28. Bozkurt A, Karabakan M, Keskin E, et al. Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Int.* Nov 2016;96(2):202-206. PMID 26613256
29. Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol.* Oct 2015;68(4):643-652. PMID 25937539
30. Ray A, Morgan H, Wilkes A, et al. The Urolift System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a NICE Medical Technology Guidance. *Appl Health Econ Health Policy.* Oct 2016;14(5):515-526. PMID 26832146
31. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int.* May 2017;119(5):767-775. PMID 27862831
32. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol.* Jun 2017;24(3):8802-8813. PMID 28646935
33. Rukstalis D, Rashid P, Bogache WK, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. *BJU Int.* Oct 2016;118 Suppl 3:14-22. PMID 27684483
34. Roehrborn CG. Prostatic urethral lift: a unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Clin North Am.* Aug 2016;43(3):357-369. PMID 27476128
35. National Institute for Health and Care Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia [IPG475]. 2014; <http://www.nice.org.uk/guidance/ipg475/chapter/1-recommendations>. Accessed November 7, 2017.
36. National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of

benign prostatic hyperplasia [MTG26]. 2015; <https://www.nice.org.uk/guidance/mtg26>. Accessed November 7, 2017.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

